Citigroup Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $32
Citigroup analyst Yigal Nochomovitz maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and raises the price target from $29 to $32.
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $33 Price Target
HC Wainwright & Co. analyst Edward White reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $33 price target.
Syndax Pharmaceuticals Q4 EPS $(0.62) Beats $(0.65) Estimate
Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.65) by 4.62 percent. This is a 134.25 percent decrease over earnings of $1.81 per share
HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $33
HC Wainwright & Co. analyst Edward White maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and raises the price target from $31 to $33.
United Natural Foods, Ollie’s Bargain, Smith & Wesson Brands And Some Other Big Stocks Moving Lower On Wednesday
U.S. stocks traded mostly lower, with the Nasdaq Composite dropping over 60 points on Wednesday. Here are some big stocks recording losses in today’s session.
Syndax Late Tuesday Announced it Priced ~6.8M Public Share Offering of Common Stock @$22/Share
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the pricing of an underwritten public offering of 6,818,182 shares of its common stock.
Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell
• Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
Syndax Pharmaceuticals Q2 EPS $(0.62) Down From $(0.44) YoY
Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.62) per share. This is a 40.91 percent decrease over losses of $(0.44) per share from the same period last year.
